Abstract
The aim of this study was to determine whether administration of BB-10010, a synthetic stem cell inhibitor, would allow more intensive chemotherapy to be administered to patients with newly diagnosed high grade NHL. Thirteen patients were randomised to receive BB-10010 concurrently with dose-intensified BEMOP/CA chemotherapy (7 patients) or chemotherapy alone (6 patients). Although the mean neutrophil count of BB-10010 treated patients was higher following cycles 1, 2 and 3 of chemotherapy compared with those receiving chemotherapy alone, there was no difference in the mean number of cycles tolerated, blood component usage and hospital admissions due to infections. No specific toxicity of BB-10010 was identified. Whilst BB-10010 can be administered safely, it does not improve the ability of patients to tolerate intensive chemotherapy for high grade NHL.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cell Division / drug effects
-
Chemokine CCL3
-
Chemokine CCL4
-
Female
-
Growth Inhibitors / adverse effects
-
Growth Inhibitors / therapeutic use*
-
Hematopoietic Stem Cells / drug effects
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, T-Cell / drug therapy
-
Macrophage Inflammatory Proteins / therapeutic use*
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
Neutropenia / prevention & control
-
Safety
-
Thrombocytopenia / chemically induced
-
Thrombocytopenia / prevention & control
-
Treatment Failure
Substances
-
Chemokine CCL3
-
Chemokine CCL4
-
Growth Inhibitors
-
Macrophage Inflammatory Proteins